FDA Launches Expedited Investigational New Drug (IND) Pilot Program

The U.S. Food and Drug Administration (FDA) announced the final design of its Expedited Investigational New Drug (IND) Pilot, a program aimed at accelerating clinical trial timelines and eliminating regulatory hurdles to maintain American leadership in global medical innovation. Driven by a presidential directive, the pilot seeks to speed up the process from identifying a drug to initiating a first-in-human clinical trial by partnering drug companies with qualified research institutions. The FDA will accept applications to participate in the pilot until October 30, 2026.